Medical imaging AI company receives approval for CINA-CSpine algorithm enabling detection and triage of cervical spine fractures.
LA CIOTAT, France, Sept. 19, 2024 /PRNewswire/ — Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-CSpine tool. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
CINA-CSpine is an AI tool designed to support the detection and triage of cervical spine fractures from CT images. Commonly caused by traumatic injury, a cervical spine fracture is a break in one or more of the seven vertebrae in the neck that can lead to spinal cord injury, resulting in neurological damage or even paralysis.
While the prognosis for cervical spine fractures depends on the severity of the injury, the timeliness of treatment is key, so prompt detection and appropriate treatment are crucial for optimizing outcomes and minimizing long-term complications. CINA-CSpine automatically flags suspected positive findings compatible with acute cervical spine fractures, seamlessly alerting radiologists through their existing systems.
“Cervical spine fractures are serious injuries that require prompt and appropriate medical attention, especially if the spinal cord is involved, so accurate diagnosis is essential,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI. “With CINA-CSpine, we aim to help reduce the delay between scan and interpretation, which is critical in the treatment of this condition.”
In addition, while missed findings are relatively rare, failure to diagnose a cervical spine injury is frequently subject to litigation. With average legal costs in the US estimated to be around $3 million, and settlements reaching as high as $9 million, an AI tool like CINA-CSpine can provide a second set of eyes to help avoid missed findings.
CINA-CSpine was validated on more than 300 non-contrast CT scans provided by multiple sources in the US and Europe, and acquired from 36 different scanner models across five vendors. The device achieved an overall sensitivity and specificity of 90.3% and 91.9%, respectively, when compared to the ground truth established by the consensus of three US-board certified senior radiologists.
“These results demonstrate that our CINA-CSpine algorithm is capable of providing prompt and accurate findings that could positively guide physicians towards better assessments and improved patient outcomes,” added Di Grandi.
CINA-CSpine is the latest tool from Avicenna.AI to secure FDA clearance, joining its AI solutions for automatic detection of a host of conditions from CT-scan imaging. All of the company’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
Avicenna.AI’s product portfolio also includes seven other AI tools for the prevention and detection of:
Intracranial hemorrhage (CINA-ICH)Large vessel occlusion (CINA-LVO)Aortic dissection (CINA-AD)Pulmonary embolism (CINA-PE and CINA-iPE)Vertical compression fractures (CINA-VCF)And ASPECT Score for quantification of stroke severity (CINA-ASPECTS).
About Avicenna.AI
Founded in 2018, Avicenna.AI specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify severe pathologies from CT medical images. Co-founded by Cyril Di Grandi, a successful entrepreneur who previously co-founded Olea Medical, and Dr. Peter Chang, an internationally recognized radiologist, and an expert in AI and deep learning, Avicenna.AI aims to accelerate therapeutic decision-making processes and enhance patient outcomes through its AI-based radiology solutions. For additional details, stay connected with us on social media and explore Avicenna.AI’s website at www.avicenna.ai.
For more information, contact:
Stéphanie Bellavia, Marketing Manager, Avicenna.AI
Email: stephanie.bellavia@avicenna.ai
View original content:https://www.prnewswire.co.uk/news-releases/avicennaai-lands-fda-clearance-for-ai-tool-that-detects-cervical-spine-fracture-302253136.html
